Cynvenio and CollabRx Announce Partnership for Cancer Molecular Diagnostics
Westlake Village, CA (PRWEB) December 11, 2013 -- Cynvenio, a cancer diagnostics company focused on transforming cancer treatment and management through the genomic analysis of tumor cells in blood, today announced a multi-year agreement with CollabRx, Inc., a data analytics company focused on informing clinical decision making in molecular medicine, to offer clinical actionable reports built from CollabRx data and information services with Cynvenio genomic tests.
Under this agreement, Cynvenio will access multiple CollabRx products including the Genetic Variant Annotation (GVA) ServiceTM to offer clinically relevant data and reporting solutions with Cynvenio’s ClearID Breast Cancer and LiquidBiopsy® genomic testing services. ClearID is a monitoring test for breast cancer survivors at high risk of disease recurrence. The ClearID blood test analyzes circulating tumor cells for cancer-associated genomic mutations which can be used to characterize disease status and available treatment options. Clinicians and researchers ordering genomic tests from Cynvenio will now have the option to also choose GVA-based reporting on identified mutations that includes a summary of the clinical evidence for treatment planning, approved targeted therapies, relevant clinical trials for investigational therapies, and additional references for further research.
"A contextualized interpretation of sequencing results is required to make the results of genomic tests actionable for physicians providing highly personalized cancer treatments to their patients," said André de Fusco, CEO of Cynvenio. "CollabRx has developed a scalable process and software platform to provide key elements of the reporting solution that Cynvenio provides to aid physicians in the clinical interpretation of tumor-specific molecular profiles. We are pleased to be able to include GVA with our molecular testing services."
"Cynvenio has introduced an innovative blood test to help monitor for disease in breast cancer survivors at high risk for recurrence,” said Thomas Mika, Chairman, President & CEO of CollabRx. "Their approach of combining the detection of circulating tumor cells with genomic analysis is important for the early detection of cancer, choice of therapy, and ultimately to achieve the best possible clinical outcomes for breast cancer patients. We chose to extend CollabRx expertise and services to ‘liquid biopsy’ for the first time with Cynvenio because they are at the forefront of the sector with a strong focus on advancing personalized medicine in cancer."
Cynvenio and CollabRx representatives will be on hand to discuss and demonstrate the ClearID Breast Cancer test with the GVA reporting service this week at the San Antonio Breast Cancer Symposium, a leading forum for clinical oncologists specializing in the treatment of breast cancer that is being held from December 10-14 in San Antonio, Texas.
The companion announcement from CollabRx is available on: http://www.collabrx.com.
About Cynvenio Biosystems, Inc.
Cynvenio is a cancer diagnostics company focused on transforming cancer treatment and management through the molecular analysis of tumor biomarkers in the bloodstream. This expertise has resulted in two distinct product offerings: ClearID Breast Cancer monitoring program and LiquidBiopsy. ClearID Breast Cancer, designed for use by patients and their physicians, is a cancer detection and monitoring program that assesses 50 oncogenes for more than 4,500 genetic mutations using next-generation sequencing. This test and real-time molecular analysis provide actionable information that can inform treatment considerations and help improve treatment outcomes. LiquidBiopsy is designed for industry and academic researchers to identify the presence of tumor-cell genetic mutations in whole blood. Founded in 2008, Cynvenio is headquartered in Westlake Village, Calif. (Los Angeles). For more information visit http://www.cynvenio.com. LiquidBiopsy® is a registered trademark of Cynvenio Biosystems, Inc.
About CollabRx
CollabRx, Inc. is a recognized leader in cloud-based expert systems to inform healthcare decision-making. CollabRx uses information technology to aggregate and contextualize the world’s knowledge on genomics-based medicine with specific insights from the nation’s top cancer experts, starting with the area of greatest need: advanced cancers in patients who have effectively exhausted the standard of care. More information may be obtained at http://www.collabrx.com.
Heidi Brown, Cynvenio, +1 805-777-0017 Ext: 703, [email protected]
Share this article